Chartwell Pharmaceuticals
Christina Settle has extensive experience in regulatory affairs, currently serving at Chartwell Pharmaceuticals since March 2017, where responsibilities include the preparation, review, and submission of ANDA amendments, supplements, annual reports, and PADERS in eCTD format, along with the successful submission of an NDA. Prior to this, Christina worked as a Regulatory Affairs Consultant at Virtus Pharmaceuticals, focusing on ANDA supplements and labeling submissions to the FDA, and at Cipla Limited, where responsibilities included reviewing ANDA submissions for the India regulatory team. Earlier roles included positions at Actavis, where coordination for ANDA submissions was key, and at Abrika Pharmaceuticals, contributing to both ANDA submissions and DEA compliance. Christina holds an Associate of Arts degree in Communications from Palm Beach State College and has further educational qualifications from Florida Atlantic University.
This person is not in any offices
Chartwell Pharmaceuticals
CHARTING A COURSE TO WELLNESS Chartwell Pharmaceuticals is a US-based development, manufacturing and commercial organization located in Congers, New York. Our facility produces prescription pharmaceutical products with a commitment to superior quality, compliance, and customer service. Chartwell Pharmaceuticals has a long history as a preferred manufacturing partner for prescription solid dosage products in tablet, capsule, and powders forms. Recent expansion now adds capabilities for suspensions, enemas and liquids manufacturing - including Unit Dose cups. Our rooms are large, our ceilings are high, and facilities are pristine. Our exceptional hands-on leadership team and technical staff bring decades of pharmaceutical industry experience in manufacturing and analytical services for development, scale-up, transferring, changing, launching, and supplying products. Under our own Chartwell labels, our mission is to provide a consistent, timely and quality product supply to our pharmacy customers and their patients. Our current portfolio stands at over 250 Orange Book listed ANDAs and NDAs, with an aggressive asset development and acquisition program in place. Supported by Chartwell Labs, our Formulations and Analytical team, we are quickly continuing to broaden our line through commercial Chartwell-labeled branding. Chartwell Pharmaceuticals is proud to be manufacturing "Made in the USA" products.